Przeglądaj według autora "Frąk, Małgorzata"

Wyświetlanie pozycji 1-3 z 3

    • Attempting to identify bacterial allies in immunotherapy of NSCLC patients 

      Grenda, Anna; Iwan, Ewelina; Krawczyk, Paweł; Frąk, Małgorzata; Chmielewska, Izabela; Bomba, Arkadiusz; Giza, Aleksandra; Rolska-Kopińska, Anna; Szczyrek, Michał; Kieszko, Robert; Kucharczyk, Tomasz; Jarosz, Bożena; Wasyl, Dariusz; Milanowski, Janusz (MDPI, 2022)
      Introduction: Factors other than PD-L1 (Programmed Death Ligand 1) are being sought as predictors for cancer immuno- or chemoimmunotherapy in ongoing studies and long-term ob- servations. Despite high PD-L1 expression ...

    • Gut microbial predictors of firstline immunotherapy efficacy in advanced NSCLC patients 

      Grenda, Anna; Iwan, Ewelina; Kuźnar-Kamińska, Barbara; Bomba, Arkadiusz; Bielińska, Katarzyna; Krawczyk, Paweł; Chmielewska, Izabela; Frąk, Małgorzata; Szczyrek, Michał; Rolska-Kopińska, Anna; Jankowski, Tomasz; Kieszko, Robert; Milanowski, Janusz (Nature, 2025)
      The composition of the gut microbiome of patients with advanced non-small cell lung cancer is currently considered a factor influencing the effectiveness of treatment with immune checkpoint inhibitors. We aimed to evaluate ...

    • Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer 

      Grenda, Anna; Iwan, Ewelina; Chmielewska, Izabela; Krawczyk, Paweł; Giza, Aleksandra; Bomba, Arkadiusz; Frąk, Małgorzata; Rolska, Anna; Szczyrek, Michał; Kieszko, Robert; Kucharczyk, Tomasz; Jarosz, Bożena; Wasyl, Dariusz; Milanowski, Janusz (Springer Open Journal, 2022)
      The significance of Akkermansia bacteria presence in gut micobiome, mainly Akkermansia mucinifila, is currently being investigated in the context of supporting therapy and marker for response to immunotherapy in cancer ...